TESARO Inc (TSRO) was Initiated by Robert W. Baird to “Outperform” and the brokerage firm has set the Price Target at $105. Robert W. Baird advised their investors in a research report released on Jul 19, 2016.
Many Wall Street Analysts have commented on TESARO Inc. Company shares were Reiterated by Mizuho on Jul 5, 2016 to “Buy”, Firm has raised the Price Target to $ 94 from a previous price target of $67 .TESARO Inc was Downgraded by Jefferies to ” Hold” on Jun 30, 2016. Company shares were Reiterated by FBR Capital on Jun 29, 2016 to “Outperform”, Firm has raised the Price Target to $ 93 from a previous price target of $65 .
On the company’s financial health, TESARO Inc reported $-2.22 EPS for the quarter, missing the analyst consensus estimate by $ -0.54 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-1.68. The company had revenue of $.31 million for the quarter, compared to analysts expectations of $3.54 million. During the same quarter in the previous year, the company posted $-1.30 EPS.
TESARO Inc opened for trading at $86.31 and hit $88.74 on the upside on Friday, eventually ending the session at $88.05, with a gain of 2.00% or 1.73 points. The heightened volatility saw the trading volume jump to 6,13,850 shares. Company has a market cap of $4,037 M.
In a different news, on Jul 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 12,500 shares at $74.02 per share price. According to the SEC, on Jun 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $41.21 per share price. On Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price, according to the Form-4 filing with the securities and exchange commission.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.